bevacizumab + docetaxel + nedaplatin

This refers to a specific therapeutic regimen evaluated in a Phase II clinical trial (NCT01210690) led by Sun Yat-sen University for the treatment of locally advanced lung adenocarcinoma. The protocol consists of concurrent chemoradiotherapy (CCRT) using weekly docetaxel and nedaplatin combined with chest radiation, followed by maintenance therapy with bevacizumab. Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis. Docetaxel is a taxane-based microtubule stabilizer that arrests cell division, while nedaplatin is a second-generation platinum analogue that induces DNA cross-linking to inhibit replication. The study aims to determine the efficacy and safety of adding bevacizumab maintenance to standard definitive chemoradiotherapy in this patient population.

Brand names

AvastinTaxotereAqupla

Other names

bevacizumab maintenance after chemoradiotherapydocetaxel + nedaplatin + radiation followed by bevacizumab